AstraZeneca PLC (NASDAQ:AZN) Shares Bought by Brown Brothers Harriman & Co.

Brown Brothers Harriman & Co. lifted its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 7.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,506 shares of the company’s stock after purchasing an additional 444 shares during the quarter. Brown Brothers Harriman & Co.’s holdings in AstraZeneca were worth $507,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of AZN. McClarren Financial Advisors Inc. raised its position in AstraZeneca by 320.8% in the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after acquiring an additional 247 shares in the last quarter. GHP Investment Advisors Inc. bought a new stake in shares of AstraZeneca in the 2nd quarter worth approximately $26,000. Capital Performance Advisors LLP acquired a new stake in AstraZeneca during the third quarter valued at approximately $28,000. Pathway Financial Advisers LLC bought a new stake in AstraZeneca during the first quarter worth approximately $29,000. Finally, Hobbs Group Advisors LLC acquired a new position in AstraZeneca in the second quarter worth approximately $35,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Stock Down 0.1 %

Shares of AstraZeneca stock opened at $66.36 on Wednesday. AstraZeneca PLC has a 1 year low of $60.47 and a 1 year high of $87.68. The company has a market cap of $205.76 billion, a P/E ratio of 31.75, a P/E/G ratio of 1.22 and a beta of 0.47. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. The stock has a 50-day moving average price of $72.94 and a 200 day moving average price of $77.65.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business had revenue of $13.57 billion during the quarter, compared to analyst estimates of $13.08 billion. During the same period in the prior year, the firm earned $0.87 earnings per share. The firm’s revenue was up 18.0% compared to the same quarter last year. As a group, analysts expect that AstraZeneca PLC will post 4.1 EPS for the current fiscal year.

Analyst Ratings Changes

AZN has been the subject of a number of recent research reports. TD Cowen increased their price objective on AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. UBS Group raised AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Finally, Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.